Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple
- PDF / 1,784,447 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 111 Downloads / 152 Views
CORRECTION
Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma Martin Kaiser 1,2 & Meral Beksaç 3 & Nina Gulbrandsen 4 & Fredrik Schjesvold 4 & Roman Hájek 5 & Philippe Moreau 6 & Felipe de Arriba de la Fuente 7 & María-Victoria Mateos 8 & Sharon West 1 & Andrew Spencer 9 & S. Vincent Rajkumar 10 & Kaveri Suryanarayan 11 & Michael Czorniak 11 & Cong Li 11 & Zhaoyang Teng 11 & Richard Labotka 11 & Meletios A. Dimopoulos 12
# Springer-Verlag GmbH Germany, part of Springer Nature 2020
Correction to: Annals of Hematology https://doi.org/10.1007/s00277-020-04149-5 Low-resolution figures were inadvertently created during production and published. These have been replaced with the high-resolution figures that were originally provided by the authors. No changes have been made to the data presented within the figures or to any other manuscript content. Please see below for the high-resolution figures:
The online version of the original article can be found at https://doi.org/ 10.1007/s00277-020-04149-5 * Martin Kaiser [email protected]
7
Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer y Centro Regional de Hemodonación, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain
1
Department of Haematology, The Royal Marsden Hospital, London, UK
8
Department of Hematology, University Hospital of Salamanca, CIC, IBM CC, Salamanca, Spain
2
Division of Molecular Pathology, The Institute of Cancer Research (ICR) and The Royal Marsden Hospital, 123 Old Brompton Road, London SW7 3RP, UK
9
Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia
10
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
11
Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA
12
Hematology and Medical Oncology, Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
3
Department of Hematology, Ankara University, Ankara, Turkey
4
Oslo Myeloma Center, Oslo University Hospital, and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway
5
Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic
6
Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France
Ann Hematol Fig. 1 CONSORT diagram. Reproduced with permission from Dimopoulos MA, Gay F, Schjesvold F et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINEMM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2019;393:253–264
Ann Hematol
a 20 Ixazomib: All grades Ixazomib: Grade 3 or 4 Placebo: All grades Placebo: Grade 3 or 4
18 16 Cumulative incidence
14 12 10 8 6 4 2 0 0
5
10
15
20
Months from date of first dose
b 220
Median platelet result (109/L)
210 200 190 180 170
EO
T
160
SE C2 D1 C3 D1 C4 D1 C5 D1 C6 D1
Data Loading...
